The role of mucolytic therapy in the treatment of sinobronchial syndrome

Zaytseva O.V.

doi:https://doi.org/

Zaytseva O.V.

Otdel patologii setchatki i zritel'nogo nerva FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdravsotsrazvitiia Ross

SPIN RSCI: 4962-5446
ORCID: 0000-0002-4975-1310

The role of mucolytic therapy in the treatment of sinobronchial syndrome

Authors:

Zaytseva O.V.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2012;77(2): 63‑65

Read: 1839 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zaytseva OV. The role of mucolytic therapy in the treatment of sinobronchial syndrome. Russian Bulletin of Otorhinolaryngology. 2012;77(2):63‑65. (In Russ.)

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Clinical efficiency of polyvalent piobacteriophage in the complex treatment of nosocomial sinusitis. Russian Bulletin of Otorhinolaryngology. 2025;(4):33-38

Comparative characteristics of the microbial landscape of the maxillary sinus in patients with chronic dacryocystitis and chronic sinusitis. Russian Rhinology. 2025;(2):117-125

Prevalence of deformities and perforations of the nasal septum and their influence on the paranasal sinuses state according to cone-beam computed tomography. Russian Rhinology. 2025;(2):126-130

Abstract:

The objective of the present study was to estimate the therapeutic efficacy and safety of myrtol standardized (gelomyrtol forte) and acetylcysteine given to 11 and 13 patients respectively presenting with sinobronchial syndrome. Dynamics of clinical and roentgenological signs and symptoms in these patients was investigated throughout the period of therapy. The best clinical results were obtained using myrtol standardized. Specifically, the summary score characterizing the change of clinical symptoms decreased from the initial value of 32 to 0.73 on the 7th day after the initiation of therapy and to 0.18 after its termination. The decrease of the same parameter in the group of the patients treated with acetylcysteine to 1.3 and 0.38 (mean score for the group) was documented on days 7 and 10 after the beginning of therapy respectively.

Keywords:

sinusitis

bronchitis

sinobronchial syndrome

mucolytic agents

myrtol standardized

gelomyrtol forte

Authors:

Zaytseva O.V.

Otdel patologii setchatki i zritel'nogo nerva FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdravsotsrazvitiia Ross

SPIN RSCI: 4962-5446
ORCID: 0000-0002-4975-1310

Close metadata

References:

Kunel'skaya N.L., Kryukov A.I., Turovskii A.B. Simptomaticheskaya terapiya pri zabolevaniyakh verkhnikh dykhatel'nykh putei. Spravochnik poliklinicheskogo vracha. M 2007; 2: 4-6.
Luchikhin L.A., Polyakova T.S. Diagnostika i lechenie ostrogo sinusita. Rus med zhurn 2004; 12: 4: 204: 199-203.
Suzuki H., Ikeda K. Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment. Current Drug Targets - Inflammation & Allergy 2002; 1: 117-126.
Beuscher N., Bien E., Elstner E.F., Kietzmann M., Amon U.E. Myrtol standardized in treatment of sinusitis and bronchitis - Pharmacodynamics and pharmacokinetics, Zeitschrift fr Phytotherapie, Abstractband, Kongress der Gesellschaft fr Phytotherapie. Wursburg 1997; 9-10.
Behrbohm H., Kaschke O., Sydow K. Der Einfluss des pflanzlichen Sekretolytikums Gelomyrtol® forte auf die mukoziliäre Clearance der Kiefernhöhle, Laryngo-Rhino-Otol 1995; 74: 733-737.
Gramann J., Hippeli S., Dornisch K. Rohnert U., Beuscher N., Elstner E.F. Antioxidant Properties of Essential Oils, Arzneim. Forsch. DrugRes 2000; 50: I: 135-139.
Hippeli S., Grabmann J., Dornisch K., Rohnert U., Elstner E.F. Freie Radikale in Pathogenese und Therapie von entzndlichen Erkrankungen des Bronchialsystems. In: Meister R., Entzndliche Erkrankungen des Bronchialsystems. Berlin Springer Verlag 2000; 1-25.
Beuscher N., Kietzmann M., Bien E., Champeroux P. Interference of Myrtol standardized with inflammatory and allergic mediators. Arzneim-Forsch. Drug Res 1998; 48: I: 985-989.
Federspiel P., Wulkow R., Zimmermann T. Wirkung von Myrtol standardisiert bei der Therapie der akuten Sinusitis - Ergebnisse einer doppelblinden, randomosierten Multizenterstudie gegen Plazebo/ Laryngo-Rhino-Otol 1997; 76: 23-27.
Zengeshpaik G.-K., Tsimmermann T., Paiske K., de Mai K. Mirtol standartizirovannyi v lechenii ostrykh i khronicheskikh zabolevanii dykhatel'nykh putei u detei. Mnogotsentrovoe postregistratsionnoe issledovanie primeneniya preparata. Issledovanie lekarstvennykh sredstv. Otdel'nyi vypusk. Arzneim. Forsch/Drug Res 1998; 48: I: 10: 990-994.